Isomorphic Labs
Isomorphic Labs is an AlphabetAlphabetAlphabet is an American technology holding company formed in 2015 through a restructuring of Google, whose businesses include Google as well as companies in autonomous driving, life sciences, and early-stage technology investment. The group reports its businesses as Google Services, Google Cloud, and Other Bets.Open the full entry company that uses artificial intelligence to design and develop medicines. It was founded by Demis HassabisDemis HassabisDemis Hassabis is a British artificial intelligence researcher and entrepreneur, co-founder of DeepMind and its CEO and that of Google DeepMind from 2010 to 2026, and since then Chair of Google DeepMind, Chief Scientist of Alphabet and CEO of Isomorphic Labs; a former chess prodigy and game designer, he shared the 2024 Nobel Prize in Chemistry with John Jumper for AlphaFold’s protein structure prediction, and has appeared twice on the Lex Fridman Podcast.Open the full entry, who is its CEO.
Contents29 sections
Key facts
February 24, 2021Incorporated in the United Kingdom
Isomorphic Labs’ legal entity, ISOMORPHIC LABS LIMITED, was incorporated at Companies House on February 24, 2021 as a private limited company, company number 13223825, with its nature of business registered as activities of head offices (SIC 70100). On the same day Valentine Anthony Bohan and Kenneth Hohee Yi were appointed directors and Abogado Nominees Limited was appointed company secretary.[1][2]
Alphabet Inc., a corporation governed by the law of the State of DelawareDelawareDelaware is a U.S. state in the Mid-Atlantic region on the East Coast, with its capital at Dover and Wilmington as its largest city. On December 7, 1787, it became the first state to ratify the U.S. Constitution, entering the Union as the 1st state, and it had a population of 989,948 in the 2020 census (April 1, 2020).Open the full entry (registration number 5786925 with the Delaware Secretary of State), was notified on February 24, 2021 as the company’s person with significant control, owning 75% or more of the shares and voting rights and holding the right to appoint or remove directors.[3]
November 2021Public Launch as an Alphabet Company
Alphabet announced Isomorphic Labs in November 2021; the launch article on the company’s website is dated November 1. The company was set up as a commercial venture building on DeepMindGoogle DeepMindGoogle DeepMind is Google’s artificial intelligence research organization, formed in April 2023 by merging DeepMind, which Google acquired in 2014, with the Brain team from Google Research, and led by CEO Demis Hassabis. It developed AlphaGo, AlphaFold, and the Gemini family of models, and Hassabis and John Jumper received the 2024 Nobel Prize in Chemistry for AlphaFold’s protein structure prediction work.Open the full entry’s AlphaFold2 breakthrough in protein structure prediction; it planned to partner with pharmaceutical and biomedical companies and began hiring a multidisciplinary team. The company set out its aim: “We are reimagining the entire drug discovery process from first principles with an AI-first approach.”[4][5]
The company was led by Demis Hassabis. DeepMind’s AI research remained separate from the new company but could be shared with it. Hassabis described biology as “an information processing system, albeit an extraordinarily complex and dynamic one,” and suggested that, while biology is probably too messy to reduce to simple equations, AI may suit it as mathematics suits physics. The name reflects the idea that information systems and biological systems may share an underlying structure; “isomorphic” means “alike in shape but having a different origin.”[5]
Colin Murdoch recalled that after AlphaFold2 appeared, he and Demis Hassabis began asking what they could do with it: “When AlphaFold came along, I think Demis and I looked at this and we thought, ‘Well, what could we do with AlphaFold?’” After months of work the two put together a business plan and pitched it to Alphabet, which decided to spin Isomorphic Labs out of DeepMind. GoogleGoogleGoogle is an American technology company founded by Larry Page and Sergey Brin and incorporated in 1998. It became an Alphabet subsidiary in 2015. Its businesses include internet search, advertising, software platforms, cloud computing, and artificial intelligence.Open the full entry invested in the company in November 2021, an amount never disclosed; Murdoch was part of the founding team.[6]
May 1, 2022First Phase of the Management Team
In early 2022 the team numbered just over a dozen people working out of a temporary office in King’s Cross, London. Not all of the DeepMind employees who had worked on Isomorphic stayed after the spinout, so the leadership hired a new team, starting with the C-suite; the first executive hires included a chief technology officer, chief AI officer, chief scientific officer and chief people officer.[6]
On May 1, 2022, London-headquartered Isomorphic Labs announced the first phase of its management team: Demis Hassabis as founder and acting CEO, while also CEO of DeepMind; Miles Congreve, PhD, as Chief Scientific Officer, previously CSO of Sosei Heptares, director of chemistry at Astex Pharmaceuticals and a team leader in medicinal chemistry and chemical technologies at GlaxoSmithKline; Sergei Yakneen, PhD, as Chief Technology Officer, previously SVP and CTO of SOPHiA GENETICS with senior roles at AmazonAmazonAmazon is a publicly traded U.S. technology and retail company founded by Jeff Bezos in 1994, with its principal corporate offices in Seattle. Its businesses span e-commerce, logistics and fulfillment, digital advertising, membership and entertainment services, consumer electronics, and Amazon Web Services cloud computing.Open the full entry, BPS Inc., the Ontario Institute for Cancer Research and EMBL; and Max JaderbergMax JaderbergMax Jaderberg is a machine learning researcher and president of Isomorphic Labs. After studying computer vision at Oxford and co-founding the image recognition company Vision Factory, he led an open-ended learning research team at Google DeepMind. He joined Isomorphic Labs at its founding in 2021 and served as chief AI officer, overseeing research that included AlphaFold 3.Open the full entry, PhD, as Director of Machine Learning, previously a DeepMind research scientist leading the Open-Ended Learning team and co-founder and CEO of Vision Factory, which Google acquired in 2014.[7]
Hassabis said: “The phenomenal success of AlphaFold demonstrated the huge impact that AI methods can potentially have on biology.”[7]
January 9, 2023Scientific Advisory Board
On January 9, 2023, the company announced in London its inaugural Scientific Advisory Board of four Nobel laureates: Jennifer Doudna (2020 Nobel PrizeNobel PrizeThe Nobel Prize is an international award established under the will of Alfred Nobel, comprising five prizes in physics, chemistry, physiology or medicine, literature and peace, awarded since 1901; its funds are managed by the Nobel Foundation, whose Board is based in Stockholm. The Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel, established in 1968, is not a Nobel Prize.Open the full entry in Chemistry for co-inventing CRISPR; founder and president of the Innovative Genomics Institute and professor at UC BerkeleyUniversity of California, BerkeleyThe University of California, Berkeley (UC Berkeley) is a campus of the University of California system; the University of California was founded in 1868 through a merger of two institutions and moved to Berkeley, California, in 1873.Open the full entry); Sir David MacMillan (2021 Nobel Prize in Chemistry for asymmetric organocatalysis; chemistry professor at Princeton UniversityPrinceton UniversityPrinceton University is a private university and Ivy League member in Princeton, New Jersey. Chartered on October 22, 1746 as the College of New Jersey, it moved to Princeton in 1756 and adopted its present name in 1896. Undergraduate education leads to A.B. and B.S.E. degrees and emphasizes small-group discussion, independent research and residential college life. Graduate education spans the humanities, social sciences, natural sciences and engineering. As of October 2026, Christopher L. Eisgruber was president. Its 2026–27 operating budget was $3.407 billion, including $342 million for undergraduate aid.Open the full entry, knighted in 2022); Sir Paul NurseSir Paul NurseSir Paul Nurse (born 1949) is a British geneticist and cell biologist whose work on fission yeast identified key regulators of the cell cycle, for which he shared the 2001 Nobel Prize in Physiology or Medicine with Leland H. Hartwell and Tim Hunt. He served as President of The Rockefeller University and of the Royal Society, became Director of the Francis Crick Institute in 2010 and became Chancellor of the University of Bristol in 2017.Open the full entry (2001 Nobel Prize in Physiology or Medicine for discoveries on the control of cell division; director and chief executive of the Francis Crick Institute and former President of the Royal Society); and Venki Ramakrishnan (2012 Nobel Prize in Chemistry for ribosome research; group leader at the MRC Laboratory of Molecular Biology in Cambridge, President of the Royal Society 2015–2020).[8]
May 2023Second Location in Lausanne
On May 30, 2023, the company announced its second location after its King’s Cross headquarters in London: an office in Lausanne, Switzerland, within the EPFL Innovation Park on the EPFL campus, where it was hiring computational biologists, machine learning specialists and data engineers. Chief Technology Officer Sergei Yakneen said: “We’ve chosen to expand our work to Lausanne to build on the vibrant scientific and technical community here at EPFL.”[9][10]
January 7, 2024Collaborations with Eli Lilly and Company and Novartis
On January 7, 2024, the company announced separate multi-target research collaborations with Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and Company (NYSE: LLY) is a U.S. pharmaceutical company founded in 1876 by Colonel Eli Lilly and headquartered in Indianapolis, Indiana.Open the full entry and Novartis, both focused on small molecules and combining upfront and milestone payments. The Lilly deal carried $45 million upfront and up to $1.7 billion in milestones; the Novartis deal carried $37.5 million upfront, funding for select research costs and up to $1.2 billion in performance-based payments. The company stated that the two partnerships could be worth nearly $3 billion to it, excluding royalties on future drug sales.[11][12]
Hassabis said: “We’re thrilled to embark on this partnership and apply our proprietary technology platform.” Fiona Marshall, President of Biomedical Research at Novartis, said: “Cutting-edge AI technologies ... hold the potential to transform how we discover new drugs.”[12]
March 2024Colin Murdoch Becomes First President
Colin Murdoch joined from Google DeepMind as Isomorphic Labs’ first President while continuing as CBO at Google DeepMind, responsible for running the business day to day and executing the company’s strategy and vision, guided by CEO Demis Hassabis. He said, “Demis and I have worked together for almost ten years,” and “Before Iso was Iso, it was an idea at DeepMind.” The company then had offices in London and Lausanne.[13]
May 8, 2024AlphaFold 3 with Google DeepMind
On May 8, 2024, Google DeepMind and Isomorphic Labs released AlphaFold 3, which predicts the 3D structures and interactions of proteins, DNA, RNA, ligands and other molecules, with the paper published in Nature. For interactions of proteins with other molecule types it showed at least a 50% improvement over existing methods, and on the PoseBusters benchmark it was 50% more accurate than the best traditional methods without needing structural input. The free AlphaFold Server for non-commercial research was launched at the same time. Isomorphic Labs combines AlphaFold 3 with its own complementary models for drug design on internal projects and with pharmaceutical partners. On November 11, 2024, the model code and weights were released for academic use.[14]
February 18, 2025Novartis Collaboration Expanded
On February 18, 2025, the company announced that up to three additional research programs would be added to its Novartis collaboration on the same financial terms as the original agreement, which had targeted three challenging targets with small-molecule drugs. The company described the expansion as a testament to the progress of the research programs in the first year.[15][16]
March 31, 2025First External Round of $600 Million
After an 18-month courtship, a Thrive CapitalThrive CapitalThrive Capital is an investment firm led by chief executive Joshua Kushner that builds and invests in internet, software and technology-enabled companies, with investments including Cursor and Chai Discovery. Kushner is also chief executive of Thrive Holdings, a long-term holding company.Open the full entry team flew to London in late 2024 to pursue an investment. Avery Klemmer of Thrive Capital recalled that a lot of people considered the company “uninvestable” because it was a Google company.[17]
On March 31, 2025, the company announced its first external funding round, $600 million led by Thrive Capital with participation from GV and additional capital from existing investor Alphabet, to further develop its next-generation AI drug design engine and advance therapeutic programs into the clinic. Until then the company had been funded by Alphabet. Hassabis said: “This funding will further turbocharge the development of our next-generation AI drug design engine”; Joshua Kushner, founder and CEO of Thrive Capital, called it a “category-defining company.”[18][19]
In January 2025 Hassabis had said the company hoped to have its first AI-designed drug in clinical trials by the end of 2025.[19]
April 2025More Than 200 Employees
By April 2025 the company had grown to more than 200 people, having operated for several years in “quasi-stealth mode,” keeping mostly quiet about its work. It planned to use its first external funding to expand into biologics and to add compute and build more models running at greater scale with more data; Murdoch said its internal programs were primarily focused on cancer and immunology.[6]
Murdoch described building what the company calls “an interdisciplinary culture,” combining AI and drug discovery expertise. Vince Hankes, a partner at Thrive Capital, said: “It’s expensive to build a full-stack life science company.” Krishna Yeshwant, managing partner at GV, recalled that meeting Hassabis at Oxford years earlier was like “meeting a rockstar.”[6]
June 17, 2025Chief Medical Officer and US Presence
On June 17, 2025, the company appointed Ben Wolf, M.D., Ph.D., as Chief Medical Officer, based at its newly established Cambridge location, establishing its presence in the United StatesUnited StatesThe United States is a federal country in North America made up of 50 states, the District of Columbia as the seat of government, and territories such as Puerto Rico and Guam; its capital is Washington, D.C. The Continental Congress adopted the Declaration of Independence on July 4, 1776. The 2020 census (April 1, 2020) counted a resident population of 331,449,281, and the 435 seats of the House of Representatives are apportioned among the states on the basis of the census.Open the full entry; the office is in Cambridge, MassachusettsMassachusettsMassachusetts (officially the Commonwealth of Massachusetts) is a state in the New England region of the northeastern United States; its capital and largest city is Boston. One of the original 13 states, it ratified the U.S. Constitution on February 6, 1788, the sixth state to do so. Its population in the 2020 census (April 1, 2020) was 7,029,917.Open the full entry.[20][21]
July 2025Preparing for First Human Trials
Speaking in Paris, Colin Murdoch said the company’s next big milestone was clinical trials: “The next big milestone is actually going out to clinical trials, starting to put these things into human beings,” adding, “We’re staffing up now. We’re getting very close.” He said researchers at its King’s Cross office in London were using AI to design cancer drugs. Besides supporting partners’ programs, the company designs its own candidates in areas such as oncology and immunology, with the aim of eventually licensing them out after early-stage trials.[22]
November 26, 2025Max Jaderberg Named Incoming President
On November 26, 2025, the company announced that Chief AI Officer Max Jaderberg would become President from January 1, 2026, succeeding Colin Murdoch, who was stepping down; the company credited Murdoch with leading the company through its “breakout phase.” Jaderberg, a founding member, had built the company’s AI approach from the ground up and led development of its AI drug design engine.[23]
January 20, 2026Collaboration with Johnson & Johnson
On January 20, 2026, the company announced a cross-modality, multi-target research collaboration with Johnson & JohnsonJohnson & JohnsonJohnson & Johnson is an American healthcare company founded in 1886, headquartered in New Brunswick, New Jersey, and listed on the New York Stock Exchange under the ticker JNJ.Open the full entry, combining its AI-first drug discovery approach with Johnson & Johnson’s drug discovery and development expertise and covering small molecules and biologics, with a focus on diseases historically out of reach. The company’s drug design engine can generate candidates for small molecules, antibodies, peptides and molecular glues. Financial terms were not stated on the announcement page.[24][16]
The same day, at Davos, Hassabis said the company expected its first clinical trials by the end of 2026.[25]
February 10, 2026IsoDDE Technical Report
On February 10, 2026, the company released a 27-page technical report, “Accurate Predictions of Novel Biomolecular Interactions with IsoDDE,” describing the Isomorphic Labs Drug Design Engine (IsoDDE), a unified computational drug-design system that goes beyond AlphaFold 3 in predictive accuracy. In the hardest generalisation category of the Runs N’ Poses benchmark it more than doubled AlphaFold 3’s accuracy; on 334 novel, low-homology antibody–antigen systems in the high-fidelity regime (DockQ > 0.8) it outperformed AlphaFold 3 by 2.3 times and Boltz-2 by 19.8 times; it surpassed all deep-learning methods on FEP+ 4, OpenFE and the CASP16 blind binding-affinity task and could surpass physics-based FEP without needing experimental crystal structures; and it could identify novel ligandable pockets, including cryptic and allosteric sites, from sequence alone in seconds.[26][27]
Mohammed AlQuraishi of Columbia UniversityColumbia UniversityColumbia University, formally Columbia University in the City of New York, is a private research university in New York City and a member of the Ivy League. Founded in 1754 by royal charter from King George II as King's College, it is the oldest institution of higher education in New York State and the fifth oldest in the United States. It was renamed Columbia College in 1784 and adopted the university name and moved to Manhattan's Morningside Heights in 1896. It has 17 schools and four affiliated colleges, with 35,978 students enrolled in fall 2025. Legal scholar Jennifer L. Mnookin became president on July 1, 2026.Open the full entry judged: “It’s a major advance, on the scale of an AlphaFold4,” but added, “we know nothing of the details.” IsoDDE is proprietary, the technical report offers scant insight into how to achieve similar results, and the company has no plans to reveal its “secret sauce.” Diego del Alamo of Takeda Pharmaceuticals noted that the company had sought industry partnerships and possibly private structural data, whose effect on performance is unclear; Gabriele Corso, a co-developer of Boltz-2, did not think proprietary data was essential. President Max Jaderberg called the company’s models “profoundly different” from other efforts and said the company had developed several versions of IsoDDE, including versions for partner work, that draw on different data sources; Michael Schaarschmidt, director of machine learning, said training data included public data, synthetic data and data sources the company will try to license.[27]
May 12, 2026$2.1 Billion Series B
On May 12, 2026, the company announced in London a $2.1 billion Series B led by Thrive Capital, with existing investors Alphabet and GV and new investors MGXMGXMGX is an Abu Dhabi artificial intelligence and advanced technology investment company, announced in March 2024 by Abu Dhabi’s Artificial Intelligence and Advanced Technology Council with Mubadala and G42 as foundational partners and chaired by Sheikh Tahnoon bin Zayed Al Nahyan. It has invested in companies including OpenAI, Anthropic, xAI, Databricks, and Binance, and co-founded the AI Infrastructure Partnership (AIP) with BlackRock, Microsoft, and others.Open the full entry, Temasek, CapitalG and the UK Sovereign AI Fund. The funds were for developing and deploying its drug design engine IsoDDE, advancing its therapeutic pipeline toward the clinic and hiring AI, engineering, drug design and clinical staff across its sites.[21][28]
Ruth Porat, President and Chief Investment Officer of Alphabet and Google, said the funding would be used to “accelerate the work and bring important interventions to market with greater speed”; Hassabis called the round “a massive vote of confidence from a diverse group of top-tier international investors”; Max Jaderberg said: “Our drug design engine works.” Krishna Yeshwant, managing partner at GV, said: “The caliber of the team Isomorphic has assembled is unmatched.”[21]
July 16, 2026Bioresilience Approach with Google DeepMind
On July 16, 2026, the company and Google DeepMind set out a joint approach to bioresilience, arguing that changing ecosystems, international travel and possible misuse of AI were increasing biosecurity threats, while AI is also a key tool for responding to them: “We need frontier AI models, and the scientific advances they will enable, to respond to these challenges.”[29]
September 29, 2026A New Path to Make Medicines with AI
On September 29, 2026, the company described itself as a vertically integrated company spanning model development, data generation, biology discovery and clinical work, which began in a one-room office, with a platform meant to work across modalities including small molecules, antibodies and peptides. It said its design agent could search chemical space autonomously over 2–4 days, where traditional work takes 1–3 months per step; that the roughly 10^60 possible drug-like small molecules dwarf the 10^5–10^9 compounds in conventional screening libraries; and that it can synthesise just a handful of molecules instead of testing thousands to millions. It showed a concentration-response curve for one agent-designed molecule, presented as one of “dozens” of examples. The company stated: “Today, AI drug discovery is no longer a hypothesis.” “Our preclinical data is helping us to gear up for clinical developments.”[30]
October 7, 2026Joins the Virtual Biology Initiative
On October 7, 2026, the company joined the Virtual Biology Initiative, convened by BiohubBiohubBiohub is a research organization combining artificial intelligence and experimental biology, founded by Priscilla Chan and Mark Zuckerberg.Open the full entry, as a founding member. The international, cross-sector effort has participants investing funding, data, computation and new measurement technology to generate and open up the data needed for predictive AI models of biology, described as “the largest coordinated commitment to generating AI-ready biological data to date.”[31]
November 2, 2026Max Jaderberg at Bloomberg Tech in London
On November 2, 2026, President Max Jaderberg predicted at Bloomberg Tech in London that AI will eventually design every drug. He said the company’s programs were “deep in pre-clinical development,” with internal programs focused on oncology, immunology and inflammation, and of its partnership model he said: “We’re not selling access to the models, we’re not selling tokens or API access.” He noted that roughly 90% of medicines entering human trials fail, that AI could help engineer molecules more precisely before patient testing, and that progress in biology still depends on real-world experiments.[25]
November 17, 2026$5 Billion Series C
On November 17, 2026, the company announced in London an oversubscribed $5 billion Series C co-led by GreenoaksGreenoaksGreenoaks is an American investment firm co-founded by Neil Mehta in 2012 and known for concentrated, long-term investing; it made an early, large bet on the Korean e-commerce company Coupang and has invested in companies including Wiz, Stripe, Databricks, and Anthropic. In May 2026, it co-led Anthropic’s $65 billion Series H funding round with Altimeter Capital, Dragoneer, and Sequoia Capital.Open the full entry and Sequoia CapitalSequoia CapitalSequoia Capital is a venture capital firm founded by Don Valentine in 1972, investing from the seed stage through the growth stage. Its historical investments include Apple, Cisco, Google, YouTube, Airbnb, and Stripe; in 2021 it introduced the Sequoia Capital Fund structure, which can continue to hold public securities, and in 2023 its regional businesses became independent brands and partnerships.Open the full entry, with Andreessen HorowitzAndreessen HorowitzAndreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz. It invests from the seed stage through the growth stage and provides operational support to its portfolio companies.Open the full entry and other new investors, continued significant investment from Alphabet, and participation from existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The funds are for maturing IsoDDE, its drug design engine unifying foundational simulation models; expanding into new biology with more advanced models; building a partner ecosystem to study mechanistic disease biology; building global infrastructure for AI-led bioengineering; and building AI-first translational and clinical development infrastructure to move drug candidates into trials. The company stated that its models were yielding positive preclinical results in oncology and immunology, internally and with partners.[32][33]
Hassabis said the company was founded on the conviction that biology can be modelled at the molecular level and accelerated by AI, and that the round would help build biology models and move its first therapeutic programs toward clinical trials; he also said: “Our drug design engine is generating molecules with unprecedented precision and speed.” President Max Jaderberg described repeatable scientific advances each week from teams pairing machine learning researchers with drug hunters. Neil MehtaNeil MehtaNeil Mehta is an investor who co-founded Greenoaks with Benny Peretz in San Francisco in 2012. The firm invested in founder-led companies including Korean retailer Coupang. In 2024 he committed $100 million to a nonprofit initiative supporting San Francisco’s Upper Fillmore commercial district.Open the full entry, founder and managing partner of Greenoaks, framed drug discovery as a very large optimization problem; Konstantine BuhlerKonstantine BuhlerKonstantine Buhler is an American venture investor and a partner at Sequoia Capital, where he works with seed and early-stage technology companies. He studied artificial intelligence at Stanford and worked at RelateIQ and Meritech Capital before backing companies in software, insurance and trading infrastructure.Open the full entry, a partner at Sequoia Capital, called the company’s work foundational technology for medicine.[32][34]
The company did not disclose the valuation; one account puts it at about $50 billion, another gives a target of up to $50 billion against roughly $17.5 billion previously. UK AI minister Kanishka Narayan called it “one of the biggest Series C rounds in UKUnited KingdomThe United Kingdom of Great Britain and Northern Ireland is a constitutional monarchy in north-western Europe. Its four constituent countries are England, Scotland, Wales and Northern Ireland. London is its capital. The union of England and Scotland in 1707, the union with Ireland in 1801 and the establishment of the Irish Free State in 1922 shaped its present territory. The Office for National Statistics put the UK’s resident population at 69,483,900 in mid-2025.Open the full entry tech history.” As of the round, none of the company’s drug candidates had entered human trials.[35][34][36]
November 19, 2026Strategic Research Collaboration with MSD
On November 19, 2026, the company announced a strategic research collaboration with MSD (the name Merck & Co.Merck & Co.Merck & Co., Inc. is a global health care company headquartered in Rahway, New Jersey, that develops medicines and vaccines and is called MSD outside the United States and Canada.Open the full entry uses outside the United States and Canada, where it is known as Merck & Co., Inc.), combining its AI approach to drug discovery with MSD’s proprietary data resources and discovery experience to advance therapeutic candidates for patient populations with unmet needs; it described IsoDDE as modality-agnostic. The collaboration also draws on MSD’s discovery, development and manufacturing expertise. Financial terms were not stated on the announcement page.[37][16][38]
Technology Platform
IsoDDE combines multiple predictive and generative AI models covering the whole process from designing a molecule to developing a potential medicine, with each step informing the next; its capabilities include structure prediction, binding-affinity prediction, blind pocket identification and navigating large chemical space, and in blind pocket identification it outperformed P2Rank by 1.4 times. The company regards AlphaFold as the basis of its founding; AlphaFold 3 was co-developed with Google DeepMind.[39]
The 2024 Nobel Prize in Chemistry was awarded half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John Jumper, then a Senior Research Scientist at Google DeepMind, “for protein structure prediction.” The two co-led the work on AlphaFold2, which debuted at the fourteenth CASP protein structure prediction competition, evaluated in 2020.[40]
Partnership Model
The company partners with pharmaceutical companies, biotechs and contract research organizations; its teams work side by side with partners throughout each program, deciding together what to design, make and test next, guided by four principles: Synergy, Collaboration, Urgency and Impact. The Eli Lilly and Company collaboration covers small-molecule drugs against several undisclosed targets. As of November 2026 the partnerships page lists Novartis, Eli Lilly and Company, Johnson & Johnson and MSD.[16]
Funding and Finances
Leadership and Scientific Advisory Board
As of November 2026 the leadership team comprises Sir Demis Hassabis (Founder and CEO), Max Jaderberg (President), Miles Congreve (Chief Scientific Officer), Sarah Korman (Chief Operating Officer), Beverley Mallon (Chief People and Experience Officer), Sarah Skerratt (Chief Research Officer) and Ben Wolf (Chief Medical Officer). The Scientific Advisory Board members are Jennifer Doudna, Sir David MacMillan, Sir Paul Nurse, Sir Menelas Pangalos and Venki Ramakrishnan.[41]
Related Organizations, Websites, and Public Accounts
Isomorphic Labs: Official website: https://www.isomorphiclabs.com/ (opens in a new window).[42]
X: Public account: https://x.com/IsomorphicLabs (opens in a new window).[42]
LinkedInLinkedInLinkedIn is a social networking platform for professionals. It was founded in 2002 by Reid Hoffman and others, launched in 2003, and listed on the New York Stock Exchange in 2011; after Microsoft acquired it for approximately $26.2 billion in 2016, it became a wholly owned Microsoft subsidiary. Its revenue comes from membership subscriptions, advertising, and recruitment solutions.Open the full entry: Public profile: https://www.linkedin.com/company/isomorphic-labs/ (opens in a new window).[42]
Sources42 sources
- ISOMORPHIC LABS LIMITED overview (opens in a new window)find-and-update.company-information.service.gov.uk↑
- ISOMORPHIC LABS LIMITED people (opens in a new window)find-and-update.company-information.service.gov.uk↑
- ISOMORPHIC LABS LIMITED persons with significant control (opens in a new window)find-and-update.company-information.service.gov.uk↑
- Introducing Isomorphic Labs (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs is Alphabet’s play in AI drug discovery (opens in a new window)techcrunch.com↑
- Inside Isomorphic Labs, the secretive AI life sciences startup spun off from Google DeepMind (opens in a new window)nbcnewyork.com↑
- Isomorphic Labs announces first phase of management team (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs announces new Scientific Advisory Board (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs announces new Lausanne location (opens in a new window)isomorphiclabs.com↑
- Announcements (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs kicks off 2024 with two pharmaceutical collaborations (opens in a new window)isomorphiclabs.com↑
- Isomorphic inks deals with Eli Lilly and Novartis for drug discovery (opens in a new window)techcrunch.com↑
- In conversation with… Colin Murdoch, Isomorphic Labs’ first President (opens in a new window)isomorphiclabs.com↑
- AlphaFold 3 predicts the structure and interactions of all of life’s molecules (opens in a new window)blog.google↑
- Isomorphic Labs announces Novartis collaboration expansion (opens in a new window)isomorphiclabs.com↑
- Partnerships (opens in a new window)isomorphiclabs.com↑
- Does Isomorphic Labs have what it takes to revolutionize drugmaking? (opens in a new window)statnews.com↑
- Isomorphic Labs announces $600m external investment round (opens in a new window)isomorphiclabs.com↑
- DeepMind spinout Isomorphic Labs raises $600m from Thrive Capital (opens in a new window)sifted.eu↑
- Isomorphic Labs appoints Dr. Ben Wolf as Chief Medical Officer and establishes US Presence (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine (opens in a new window)aap.com.au↑
- Alphabet’s Isomorphic Labs has grand ambitions to ‘solve all diseases’ with AI. Now, it’s gearing up for its first human trials (opens in a new window)fortune.com↑
- Isomorphic Labs to appoint Max Jaderberg as President (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs enters into a research collaboration with Johnson & Johnson (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs president says all drugs will be AI-designed as first trials near a year-end target (opens in a new window)rdworldonline.com↑
- The Isomorphic Labs Drug Design Engine unlocks a new frontier beyond AlphaFold (opens in a new window)isomorphiclabs.com↑
- ‘An AlphaFold 4’—scientists marvel at DeepMind drug spin-off’s exclusive new AI (opens in a new window)scientificamerican.com↑
- Isomorphic Labs announces Series B investment round (opens in a new window)isomorphiclabs.com↑
- Our approach to bioresilience (opens in a new window)isomorphiclabs.com↑
- Building a new path to make medicines with AI (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs joins the Virtual Biology Initiative to build foundational data for AI models to predict and treat disease (opens in a new window)isomorphiclabs.com↑
- Isomorphic Labs announces $5 Billion Series C funding (opens in a new window)technode.global↑
- AI药物研发公司Isomorphic Labs宣布完成50亿美元C轮融资,由Greenoaks与红杉资本领投 [AI drug discovery company Isomorphic Labs announces $5 billion Series C led by Greenoaks and Sequoia Capital] (opens in a new window) (in Chinese)ababnews.com↑
- Isomorphic Labs raises $5bn in ‘one of UK tech’s biggest funding rounds’ (opens in a new window)cityam.com↑
- Isomorphic Labs raises $5bn in massive third round (opens in a new window)pharmaphorum.com↑
- Isomorphic Labs raises $5B series C months after $2.1B round (opens in a new window)fiercebiotech.com↑
- Isomorphic Labs enters into a strategic research collaboration with MSD (opens in a new window)isomorphiclabs.com↑
- Company fact sheet (opens in a new window)msd.com↑
- Our Tech (opens in a new window)isomorphiclabs.com↑
- The Nobel Prize in Chemistry 2024 - Popular information (opens in a new window)nobelprize.org↑
- Our Team (opens in a new window)isomorphiclabs.com↑
- News (opens in a new window)isomorphiclabs.com↑